Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VIR-5818

Other · Acts on HER2 (ERBB2) · developed by Vir Biotechnology

Phase 1/2 Most advanced trial
VIR Developer
1 Registered trials

What is VIR-5818?

VIR-5818 is an agent administered by intravenous infusion, studied in locally advanced or metastatic HER2-expressing cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Targets
HER2 (ERBB2) (antigen)
Mechanism
Acts on HER2 (ERBB2)
Therapy area
Oncology
Developer
Vir Biotechnology, Inc. (VIR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05356741 Phase 1/2 Locally Advanced or Metastatic HER2-Expressing Cancers Recruiting VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced or Metastatic HER2-Expressing Cancers

Other drugs acting on ERBB2

More from Vir Biotechnology

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.

Follow VIR, the company behind VIR-5818

See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VIR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.